George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Syncona Adds Azeria Therapeutics To Portfolio As Net Assets Take Hit

Thu, 21st Nov 2019 10:47

(Alliance News) - Syncona Ltd on Thursday said it will not be paying a dividend for the first half of its current financial year as the performance of its portfolio companies deteriorated.

In addition, the healthcare company said it has invested GBP29.5 million in a new portfolio company, Azeria Therapeutics, as part of series B financing. Syncona will now have a 61% stake.

Azeria was founded in 2017 by Sixth Element Capital, with the aim of building a pioneer factor oncology company, developing treatments for hormone resistant breast cancer patients.

Azeria received initial investment of GBP5.5 million in series A financing from the CRT Pioneer Fund, which focuses on early stage investments in oncology programmes, Syncona said.

Turning to earnings, Syncona reported net asset value per share on September 30 of 198.87 pence a share, down from 208.13p a year prior and 216.8p as at March 31.

Syncona explained that its NAV performance was hurt by the 61% fall in the share price of Autolus Therapeutics Ltd, which outweighed the GBP92.7 million gain on the sale of Blue Earth Diagnostics Ltd and uplift in the value of Achilles Therapeutics Ltd.

"We have made good progress across the portfolio and demonstrated a strong track record of success in the first half of 2019.," said Chief Executive Martin Murphy.

Syncona paid a 2.3p per share dividend for the year to the end of March, but said "it is no longer appropriate" for it to pay a dividend, without elaborating.

Looking ahead, Murphy added: "We continue to see a strong pipeline of opportunities across a broad range of therapeutic areas to found new companies and take products to market, as we seek to build a sustainable, diversified portfolio of 15-20 companies in innovative areas of healthcare."

Syncona shares were trading 1.6% lower in London on Thursday morning at 220.87 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related Shares

More News
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an in...

12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise...

8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to...

8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.